ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,460.48
      -0.41%
      US Tech 100
      19,181.60
      -0.43%
      Dow Jones
      39,118.86
      -0.12%
      Brent Oil
      85.255
      0.17%
      Bitcoin
      63,380.38
      1.13%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Incyte Corporation (INCY)

      7. Incyte Corporation (INCY) News

      INCY

      Incyte (INCY)

      Incyte Corporation
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:INCY
      DateTimeSourceHeadlineSymbolCompany
      07/11/20224:00PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      07/08/20229:56PMTipRanksRBC Capital Maintains a Buy Rating on Incyte (INCY)NASDAQ:INCYIncyte Corporation
      07/06/20224:14PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      07/06/20224:08PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      07/06/20224:07PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      07/06/20224:06PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      07/01/20224:29PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      07/01/20224:02PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      07/01/20224:02PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      07/01/20224:02PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      06/17/20224:54PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      06/17/20224:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      06/17/20224:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      06/17/20224:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      06/17/20224:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      06/17/20224:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      06/16/20224:02PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INCYIncyte Corporation
      06/15/20229:45PMTipRanksWall Street Analysts Are Bullish on Top Healthcare PicksNASDAQ:INCYIncyte Corporation
      06/15/20227:21AMTipRanksThese Stocks are the Biggest Pre-Market Movers on WednesdayNASDAQ:INCYIncyte Corporation
      06/13/20229:50PMPR Newswire (US)FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia AreataNASDAQ:INCYIncyte Corporation
      05/26/20226:22PMBusiness WireDaten aus dem robusten und fortschrittlichen Onkologie-Portfolio von Incyte werden auf dem EHA-Jahreskongress 2022 vorgestelltNASDAQ:INCYIncyte Corporation
      05/26/20223:55PMBusiness WireDes données du robuste portefeuille d’oncologie en progression d’Incyte seront présentées lors de la réunion annuelle 2022 de l’AEHNASDAQ:INCYIncyte Corporation
      05/26/20226:00AMBusiness WireData from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual MeetingNASDAQ:INCYIncyte Corporation
      05/24/20228:00AMBusiness WireIncyte to Present at Upcoming Investor ConferenceNASDAQ:INCYIncyte Corporation
      05/20/20229:05AMDow Jones NewsLilly and Incyte's Olumiant Gets CHMP Recommendation in Alopecia AreataNASDAQ:INCYIncyte Corporation
      05/20/20228:11AMPR Newswire (US)CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)NASDAQ:INCYIncyte Corporation
      05/11/20227:43AMDow Jones NewsFDA Approves Lilly, Incyte Drug Olumiant for Certain Hospitalized Covid PatientsNASDAQ:INCYIncyte Corporation
      05/11/20226:45AMPR Newswire (US)FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19NASDAQ:INCYIncyte Corporation
      05/05/20221:20AMBusiness WireIncyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host DiseaseNASDAQ:INCYIncyte Corporation
      05/05/202212:25AMTipRanksJMP Securities Remains a Buy on Incyte (INCY)NASDAQ:INCYIncyte Corporation
       Showing the most relevant articles for your search:NASDAQ:INCY